Acumen Pharmaceuticals
Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease.
Something off on this page? Send us feedback.
Profile
Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease that selectively targets toxic soluble amyloid-beta oligomers. Its central program is the ALTITUDE-AD clinical trial, while formulation and delivery initiatives seek to extend the program.
Develops sabirnetug, a humanized monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers in early symptomatic Alzheimer’s disease.
The program rests on long-running research into these oligomers and is being evaluated in ALTITUDE-AD, a Phase 2 trial of intravenous sabirnetug that spans the United States, Canada, the European Union, and the United Kingdom.
The company is also investigating a subcutaneous formulation and has described a development initiative using blood-brain-barrier technology.
With no approved commercial product identified in the dossier, operations depend on completing and reporting ALTITUDE-AD and continued development of sabirnetug, its formulation, and delivery initiatives.
Company facts
Key statistics
Year to date +44.3% · Average volume (30d) 351.2K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.36 | −$0.45 | −25.2% | — | $92.0K | — | +1.62% |
| May 12, 2026Q1 FY26 | −$0.40 | −$0.33 | +18.1% | — | — | — | +0.40% |
| Mar 26, 2026Q4 FY25 | −$0.50 | −$0.41 | +18.0% | — | — | — | −11.37% |
| Nov 12, 2025Q3 FY25 | −$0.63 | −$0.44 | +30.2% | — | — | — | −7.18% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$46.0K | $0 | |
| Operating income | −$30.4M | −$41.8M | −$26.5M | −$25.2M | −$21.1M | −$32.6M | |
| Net income | −$28.8M | −$41.0M | −$26.5M | −$25.1M | −$20.7M | −$32.7M | |
| Diluted EPS | −$0.48 | −$0.68 | −$0.44 | −$0.42 | −$0.33 | −$0.45 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $110.2M · Total debt $31.6M · Total assets $116.0M · Shareholders' equity $57.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 72.23M · Float 61.67M · 85.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 20.99M | 29.06% | 13F | May 15, 2026 |
| Sands Capital Ventures, LLC | 3.72M | 5.15% | 13F | May 8, 2026 |
| James B. Murray Jr. | 3.61M | 5.00% | 13G | Apr 7, 2026 |
| Alyeska Investment Group, L.P. | 2.45M | 3.40% | 13F | May 15, 2026 |
| Franklin Resources Inc | 2.31M | 3.19% | 13F | May 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 16, 2026 | Derrell Porter | director | −12,800 | $2.33 |
| Jun 17, 2026 | Derrell Porter | director | −13,040 | $2.33 |
| Jun 15, 2026 | Derrell Porter | director | −6,460 | $2.35 |
| Jun 9, 2026 | Nathan B. Fountain | director | −6,400 | $2.23 |
| Mar 6, 2026 | Derek M. Meisner | officer: Chief Legal Officer & Corp Sec | −2,090 | $3.26 |
Peers
- Eli Lilly
Approved anti-amyloid therapy for early symptomatic Alzheimer's disease
- Biogen
Co-commercialized anti-amyloid antibody for early Alzheimer's disease
- AC Immune
Clinical-stage active anti-Abeta immunotherapy for Alzheimer's disease
- Annovis Bio
Pivotal-stage oral therapy candidate for early Alzheimer's disease
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals | $2.92 | +0.17% | $210.9M | — | — | — | — |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| AC Immune | $2.65 | −0.56% | $269.7M | — | — | 12.5 | +498.6% |
| Annovis Bio | $1.74 | +1.16% | $73.2M | — | — | — | — |
| Median | 39.0 | 22.6 | 12.5 | +47.7% |